{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:47:46Z","timestamp":1761763666054,"version":"build-2065373602"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":353,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    To evaluate the clinical and pressure\u2010flow effects of tamsulosin 0.4\u2003mg once daily in patients with lower urinary tract symptoms (LUTS) caused by benign prostatic obstruction (BPO), as documented by pressure\u2010flow studies performed according to a standardized protocol in one centre.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and methods<\/jats:bold>\n                    A single\u2010centre study was conducted with an open\u2010label design comprising a 2\u2010week, single\u2010blind, placebo run\u2010in period and a 12\u2010week active treatment period with tamsulosin 0.4\u2003mg once daily. Eligible patients were men (aged \u200a45\u2003years) with LUTS (total International Prostate Symptom Score, IPSS, \u200a13) with a free\u2010flow maximum urinary flow rate (Q\n                    <jats:sub>max<\/jats:sub>\n                    ) of \u200a4\u2003mL\/s for a voided volume of \u200a120\u2003mL. After the 2\u2010week placebo run\u2010in period, only patients with BPO (i.e. in the obstructed zone of the Abrams\u2010Griffiths, AG, nomogram) received active treatment with tamsulosin. The two primary efficacy variables were the change in detrusor pressure at maximum flow (P\n                    <jats:sub>detQmax<\/jats:sub>\n                    ) and the total IPSS, from baseline to endpoint. A standardized protocol was used for all pressure\u2010flow studies.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    In all, 42 patients were enrolled into the 2\u2010week placebo run\u2010in period, after which 30 received active treatment with tamsulosin 0.4\u2003mg once daily. All 12 patients (29%) who discontinued during the placebo run\u2010in period failed to fulfil the pressure\u2010flow entry criterion of confirmed obstruction. The 30 patients who received tamsulosin had a high mean P\n                    <jats:sub>detQmax<\/jats:sub>\n                    (82.1\u2003cm H\n                    <jats:sub>2<\/jats:sub>\n                    O) and high mean AG number (68.1) at baseline, as would be expected in obstructed patients. Tamsulosin produced a significant reduction in mean P\n                    <jats:sub>detQmax<\/jats:sub>\n                    (\u2212\u200310.6\u2003cm H\n                    <jats:sub>2<\/jats:sub>\n                    O or \u221213%;\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.005 vs baseline). The mean AG number decreased accordingly (\u2212\u200315.5 points or \u221223%; P\u2003&lt;\u20030.001 vs baseline). The pressure\u2010flow mean Q\n                    <jats:sub>max<\/jats:sub>\n                    was increased by 2.5\u2003mL\/s (36%) from 7.0\u2003mL\/s at baseline (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.002 vs baseline). Urodynamic improvements were accompanied by a good symptomatic response; the mean total IPSS was reduced by 6.7 points from a baseline value of 18.1 (\u2212\u200337%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030.001 vs baseline). At the endpoint, 67% of patients had a clinically significant symptomatic response (defined as a decrease in total IPSS of \u200a25% from baseline). Twenty\u2010six patients (87%) were either slightly improved (13) or were much improved (13) in the opinion of the investigator. Twelve patients with LUTS who were unobstructed after the 2\u2010week placebo run\u2010in (P\n                    <jats:sub>detQmax<\/jats:sub>\n                    44.1\u2003cm H\n                    <jats:sub>2<\/jats:sub>\n                    O) received tamsulosin treatment outside of the study protocol. Although these patients had no decrease in mean P\n                    <jats:sub>detQmax<\/jats:sub>\n                    , the magnitude of the symptomatic response (decrease in total IPSS \u22126.4 or \u221234%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.001) was comparable with that in unobstructed patients; the free\u2010flow Q\n                    <jats:sub>max<\/jats:sub>\n                    was also significantly improved. Possibly or probably drug\u2010related adverse events were reported in nine patients; one discontinued tamsulosin treatment because of a serious adverse event.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    Tamsulosin 0.4\u2003mg once daily can produce a significant decrease in detrusor pressure, increase in flow rate and a symptomatic improvement in patients with LUTS and confirmed obstruction. Patients with LUTS who are unobstructed and have a low initial detrusor pressure appear to have no improvement in detrusor pressure, but have similar clinical responses to those in obstructed patients. Pressure\u2010flow studies can be reserved for those patients with LUTS who fail to respond to these agents and in whom further diagnosis and management is warranted.\n                  <\/jats:p>","DOI":"10.1046\/j.1464-410x.2001.00983.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T02:59:24Z","timestamp":1047351564000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand"],"prefix":"10.1111","volume":"87","author":[{"given":"E.P.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,4,20]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"318","article-title":"Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle\u2010aged and elderly men","volume":"43","author":"Garraway WM","year":"1993","journal-title":"Br J Gen Pract"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000052283"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957010-00002"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62836-2"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0700907"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(98)00126-5"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0022-5347(01)62386-3","article-title":"A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia","volume":"160","author":"Narayan P","year":"1998","journal-title":"J Urol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1995.tb07709.x"},{"key":"e_1_2_6_10_2","first-page":"155","article-title":"Tamsulosin, the first prostate selective \u03b11A\u2010adrenoceptor antagonist: a meta\u2010analysis of two randomized, placebo\u2010controlled multicentre studies in patients with benign prostatic obstruction (symptomatic BPH)","volume":"29","author":"Chapple CR","year":"1996","journal-title":"Eur Urol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.00205.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(98)00127-7"},{"key":"e_1_2_6_13_2","first-page":"145","article-title":"Tamsulosin, the first prostate\u2010selective \u03b11A\u2010adrenoceptor antagonist. Analysis of a multinational, multicentre, open\u2010label study assessing the long\u2010term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH)","volume":"29","author":"Schulman CC","year":"1996","journal-title":"Eur Urol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.00411.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.00380.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1520-6777(1997)16:1<1::aid-nau1>3.0.co;2-i"},{"key":"e_1_2_6_17_2","first-page":"85","volume-title":"Proceedings of the International Consultation on Benign Prostatic Hyperplasia (BPH).","author":"Aso Y","year":"1991"},{"issue":"2","key":"e_1_2_6_18_2","first-page":"78(A310","article-title":"European pressure flow investigation of tamsulosin in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) \u2013 ESPRIT study","volume":"35","author":"Abrams P","year":"1999","journal-title":"Eur Urol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00249-X"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)68149-7"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00040-4"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00490-6"},{"key":"e_1_2_6_23_2","first-page":"179","volume-title":"Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH).","author":"Koyanagi T","year":"1998"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36077-9"},{"key":"e_1_2_6_25_2","first-page":"319(A361)","article-title":"Urodynamic assessment of the efficacy of finasteride","volume":"153","author":"Glazier DB","year":"1995","journal-title":"J Urol"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-410x.2001.00983.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-410x.2001.00983.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1464-410x.2001.00983.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:46:07Z","timestamp":1761756367000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1046\/j.1464-410x.2001.00983.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1046\/j.1464-410x.2001.00983.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1464-410x.2001.00983.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2001,1]]},"assertion":[{"value":"2002-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}